Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
Stock
CALTX
CALTX News & Events
-
Add to Watchlist
Trade CALTX
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Forecast
Technical
Valuation
Financials
Earnings
Should I Buy
News
CALTX News
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Jul 26 2024
Newsfilter
Calliditas Q1 report, January - March 2024
May 23 2024
PRnewswire
Calliditas Q1 report, January - March 2024
May 23 2024
PRnewswire
Launch of Phase 3 clinical trial with Nefecon in Japan
Jul 04 2024
Newsfilter
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
May 16 2024
newsfilter
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Apr 08 2024
newsfilter
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
May 28 2024
newsfilter
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Apr 18 2024
newsfilter
Show More News
CALTX Events
No data
CALTX Monitor News
No data
CALTX Earnings Analysis
No Data
People Also Watch
